Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIIb, Controlled, Open Label, Single-Center, Persistency, Extension Study in Chinese Children After a 2+1 Dose Series of Either CRM197-Conjugate Haemophilus Influenzae Type b Vaccine or Tetanus Toxoid-Conjugate Haemophilus Influenzae Type b Vaccine

NCT02139228 is registered in ClinicalTrials.gov with Novartis Vaccines as lead sponsor.

NCT NCT02139228
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02139228 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIIb, Controlled, Open Label, Single-Center, Persistency, Extension Study in Chinese Children After a 2+1 Dose Series of Either CRM197-Conjugate Haemophilus Influenzae Type b Vaccine or Tetanus Toxoid-Conjugate Haemophilus Influenzae Type b Vaccine
Lead sponsor
Novartis Vaccines
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2014
Completion date
January 31, 2015
Enrollment
426 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

meningitis, epiglottitis, pneumonia, arthritis caused by haemophilus influenzae type b